Peer-Reviewed Publication
Lancet Reg Health Am2026;61101527.September 1, 2026Journal Article
Development and validation of a miRNA-based prognostic model for high-grade serous ovarian cancer: a retrospective cohort study.
Cristiane Esteves Teixeira1, Nayara Gusmão Tessarollo1, Glenerson Baptista1, Alessandra Freitas Serain1, Helena Zancanaro1, Diego José Gomes de Paula2, Luciana Castro Moreeuw2, Cláudia Bessa Pereira Chaves3, João P B Viola4, Alexandre Dias Porto Chiavegatto Filho5, Mariana Boroni1
1Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
2National Tumor Bank, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
3Gynecologic Oncology Department and Division of Clinical Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
4Program of Immunology and Tumor Biology, Division of Experimental and Translational Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
5Department of Epidemiology, School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.
Abstract
BACKGROUND: Ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), is the most lethal gynecological malignancy, mainly due to late-stage diagnosis and limited prognostic biomarkers. Current clinical markers, such as CA125, have limited prognostic accuracy for risk stratification. MicroRNAs (miRNAs) have emerged as promising biomarkers due to roles in tumor biology and stability in…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans